Search results for "Immunization"
CDC publishes guidance on testing for flu, COVID-19
Patients presenting with acute respiratory illness should be tested for SARS-CoV-2 with nucleic acid detection or antigen detection assay, as well as flu if the results will change clinical management or infection control decisions, the CDC said.
https://immattersacp.org/weekly/archives/2023/12/19/1.htm
19 Dec 2023
New ACIP adult immunization schedule changes flu, hepatitis A and B vaccination advice
Among other updates from the Advisory Committee on Immunization Practices, any licensed influenza vaccine that is appropriate for the age and health status of the patient may be used.
https://immattersacp.org/weekly/archives/2019/02/05/1.htm
5 Feb 2019
Q&A with ACP's President on COVID-19 vaccines
George M. Abraham, MD, MPH, MACP, ACP's President, recently discussed the difference between third shots and boosters and other complexities of vaccination, as well as offered advice to internists on getting more patients vaccinated.
https://immattersacp.org/weekly/archives/2021/11/23/1.htm
23 Nov 2021
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021
Many recent studies reporting on COVID-19 vaccines' safety, effectiveness
New studies looked at the safety of the adenovirus COVID-19 vaccines, the effectiveness of almost all the vaccines, and the impacts of COVID-19 infection in pregnancy and on long-term cardiac function. A physician columnist addressed pandemic-related anger.
https://immattersacp.org/weekly/archives/2021/05/11/1.htm
11 May 2021
New data on delta variant of COVID-19 and vaccines
Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
https://immattersacp.org/weekly/archives/2021/08/31/1.htm
31 Aug 2021
Research on COVID-19 vaccines' duration, reactions, prioritization
Antibodies persisted six months after vaccination, and a graded dosing protocol allowed patients with reactions to a first shot to get a second. Surveyed Americans wanted to prioritize front-line workers and those with chronic conditions for vaccination, and a columnist finds reasons for hope.
https://immattersacp.org/weekly/archives/2021/04/13/1.htm
13 Apr 2021
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021